The University of Chicago Header Logo

Connection

Walter M. Stadler to Urologic Neoplasms

This is a "connection" page, showing publications Walter M. Stadler has written about Urologic Neoplasms.
Connection Strength

2.391
  1. Management of Urothelial Bladder Cancer: Predicting the Future. J Oncol Pract. 2019 08; 15(8):429-430.
    View in: PubMed
    Score: 0.625
  2. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2014 Apr 01; 120(7):976-82.
    View in: PubMed
    Score: 0.423
  3. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
    View in: PubMed
    Score: 0.177
  4. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000 May; 18(9):1921-7.
    View in: PubMed
    Score: 0.165
  5. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018 04; 73(4):560-569.
    View in: PubMed
    Score: 0.140
  6. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
    View in: PubMed
    Score: 0.124
  7. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
    View in: PubMed
    Score: 0.112
  8. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
    View in: PubMed
    Score: 0.109
  9. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.
    View in: PubMed
    Score: 0.105
  10. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
    View in: PubMed
    Score: 0.098
  11. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.
    View in: PubMed
    Score: 0.083
  12. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar; 6(1):31-5.
    View in: PubMed
    Score: 0.071
  13. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs. 2007 Apr; 25(2):181-5.
    View in: PubMed
    Score: 0.064
  14. Development of growth inhibitory agents in urological and other malignancies. BJU Int. 2006 Sep; 98(3):497-502.
    View in: PubMed
    Score: 0.063
  15. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996 Oct; 156(4):1280-5.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.